NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity. Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development.
This news matters because Ebola remains a deadly disease with limited treatment options, and the development of an oral, broad-spectrum antiviral could significantly improve outbreak response and patient access. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. Unlike many antivirals that target the virus itself, NV-387’s host-directed approach may reduce the likelihood of viral resistance, a critical advantage in the fight against rapidly mutating viruses like Ebola. If successful, NV-387 could become a key tool in managing not only Ebola but also other viral threats, as the company is developing it for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and even Measles.
The trial’s progress is a significant milestone for NanoViricides, which has faced the inherent challenges of drug development. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. Its lead drug candidate, NV-387, is being developed as a treatment for a range of viral diseases. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants, but it is currently focused on advancing NV-387 into Phase II human clinical trials. For investors, the update provides a glimpse into the company’s pipeline and its potential to address unmet medical needs. The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC.
NetworkNewsWire (“NNW”), a specialized communications platform with a focus on financial news and content distribution, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
